Targeted next-generation sequencing may accurately estimate tumor mutation burden in NSCLC, which may further shed light on the likelihood of benefit from immune checkpoint inhibitors in individual patients.
A commonly used gene expression profile test for predicting breast cancer recurrence proves to be less cost-effective in a real-world setting, according to research published in the Journal of Clinical Oncology.
High levels of a specific enzyme are linked with lower survival rates in patients with multiple myeloma, according to a new study.
The US Food and Drug Administration has approved a next-generation sequencing assay that may be used as a companion diagnostic for therapy selection for solid tumors.
A recent study found that a significant number of patients with multiple myeloma harbor potentially actionable oncogenic molecular alterations, prompting a need for novel precision medicine approaches.
Investigating genetic variations within a primary tumor and additional diversity found in tumor DNA in the bloodstream could help guide and improve treatment choices in patients with gastroesophageal adenocarcinoma.
A recent study showed that after performing next-generation sequencing of non-small cell lung cancer gene panels, actionable mutations were identifiable in 65% of cases with available targeted therapeutic options.
The 70-gene signature assay for early breast cancer provides physicians with actionable information and may be associated with adjuvant therapy decisions.
Recent research has uncovered a new cause of treatment resistance in prostate cancer, which may improve targeted therapy efforts.
Clinical pathway implementation and adaptation requires proper leadership and appreciation of the nuances of organizations and patient populations, according to Aymen Elfiky, MD.